Bifidobacteria for treating diabetes and related conditions
OwnerRemy Burcelin, Didier Carcano +1inventors
InventorsREMY BURCELIN, DIDIER CARCANO, SAMPO LAHTINEN
Life of this patent
Estimating the term…
Abstract
This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly Type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions.
Claims25
1-44. (canceled)
A method of treating a disease or condition in a mammal, wherein:
- the method comprises administering to a mammal in need of such treatment a combination of (i) a bacterium of the genus Bifidobacterium and (ii) an antidiabetic drug;
- and
- the disease or condition is selected from:
- (a) diabetes;
- (b) metabolic syndrome;
- (c) impaired glucose tolerance;
- (d) reduced insulin sensitivity;
- (e) reduced fed insulin secretion;
- (f) elevated fasted insulin secretion;
- (g) obesity;
- (h) weight gain;
- (i) elevated body fat mass;
- and
- (j) elevated mesenteric fat mass.
47-51. (canceled)
The method of 45, wherein the Bifidobacterium is of the species Bifidobacterium animalis subsp. lactis strain 420 (B420).
(canceled)
Dependencies are inferred from the claim text.